An Open Label, Non-Randomised Study to Explore Safety/Tolerability, Pharmacokinetics and Pharmacodynamics of LCZ696 in Patients With Stable Heart Failure.
Phase of Trial: Phase II
Latest Information Update: 12 Jun 2015
At a glance
- Drugs Sacubitril/valsartan (Primary)
- Indications Heart failure
- Focus Adverse reactions; Biomarker; Pharmacodynamics
- Sponsors Novartis Pharmaceuticals
- 24 Dec 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 09 Dec 2009 Planned end date (July 2009) added as reported by ClinicalTrials.gov.
- 16 Jun 2009 New trial record